Asset Details
Do you wish to reserve the book?
The TAILOR study establishes, in patients mCRC wt, the first line use of FOLFOX in combination with cetuximab
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The TAILOR study establishes, in patients mCRC wt, the first line use of FOLFOX in combination with cetuximab
Do you wish to request the book?
The TAILOR study establishes, in patients mCRC wt, the first line use of FOLFOX in combination with cetuximab
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The TAILOR study establishes, in patients mCRC wt, the first line use of FOLFOX in combination with cetuximab
2022
Overview
Cetuximab in combination with chemotherapy is a standard first-line treatment regimen for patients
with metastatic colorectal cancer (mCRC) RAS wild-type
(wt); however, the efficacy of cetuximab plus leucovorin,
fluorouracil and oxaliplatin (FOLFOX) had never been
demonstrated in a prospective, randomized, controlled
phase III study. The TAILOR study is the first randomized,
multicenter, prospective Phase III study evaluating the
addition of cetuximab to FOLFOX in a RAS wt Chinese
population and thus providing confirmatory data for the
efficacy and safety of cetuximab plus FOLFOX versus
FOLFOX alone.
Publisher
Il Pensiero Scientifico Editore
We currently cannot retrieve any items related to this title. Kindly check back at a later time.